Molecular Biology Program
The Dirk Remus Lab
Research
We are interested in the mechanism of chromosome replication, a process that is highly conserved across eukaryotes and that involves the duplication of both the chromosomal DNA and its associated chromatin states. As chromosomes are the carriers of both the genetic and epigenetic information, faithful chromosome replication is of fundamental importance for genome maintenance during normal cell proliferation. Accordingly, defects in chromosome replication are a major driver of the genomic instability observed in cancer cells. To understand the molecular mechanisms by which eukaryotic cells carry out and monitor accurate genome replication we employ a fully reconstituted DNA replication system based on purified proteins from the budding yeast, S. cerevisiae. Research projects are focused on the mechanistic characterization of the DNA replication machinery, the mechanism of replication-coupled chromatin assembly, and the control of DNA replication by checkpoint genome surveillance pathways.
Featured News
Publications Highlights
People
Dirk Remus, PhD
- Molecular biologist Dirk Remus investigates mechanisms of DNA replication in eukaryotic cells.
- PhD, University of California, Berkeley
- [email protected]
- Email Address
- 212-639-5263
- Office Phone
Members
- BSc, MSc, McGill University
- Cancer Biology
Lab Alumni
Lab Affiliations
Achievements
- Louis V. Gerstner, Jr. Young Investigator Award, Memorial Sloan Kettering Cancer Center (2011)
- Long-Term Fellow, EMBO (2006)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dirk Remus discloses the following relationships and financial interests:
-
AbCellera Biologics Inc.
Equity -
Advanced Micro Devices, Inc
Equity -
Alphabet Inc
Equity -
Alpine Immune Sciences, Inc.
Equity -
Beam Therapeutics
Equity -
CRISPR Therapeutics AG
Equity -
Ginkgo Bioworks, Inc.
Equity -
INmune Bio, Inc.
Equity -
Intellia
Equity
-
Merck & Co Inc.
Equity -
Microsoft Corporation
Equity -
Moderna, Inc.
Equity -
Novo Nordisk
Equity -
NVIDIA Corporation
Equity -
Pfizer, Inc.
Equity -
Prime Medicine, Inc.
Equity -
Recursion Pharmaceuticals
Equity -
Repare Therapeutics
Equity
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].